1 Min Read
Aug 22 (Reuters) -
* Pharmakea announces successful completion of a phase 1 trial in healthy subjects for its novel loxl2 inhibitor, pat-1251 Source text for Eikon:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.